OPKO Health, Inc. 2010 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2010. OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company focused on neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company operates in two reportable segments: Pharmaceutical (including R&D and commercial operations in Chile and Mexico) and Instrumentation (ophthalmic devices). OPKO is a development-stage company with a history of operating losses, relying on equity financing and strategic collaborations to fund its pipeline.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $36.9 million | $13.1 million |
| Gross Margin | $16.4 million (44.4%) | $3.6 million (27.2%) |
| Operating Loss | $(17.2) million | $(28.0) million |
| Net Loss | $(18.9) million | $(30.1) million |
| Net Loss Attributable to Common Shareholders | $(21.6) million | $(34.8) million |
| Cash and Cash Equivalents (Year End) | $18.0 million | $42.7 million |
| Working Capital | $26.5 million | $50.8 million |
| Long-Term Debt / Credit Lines | $14.7 million (Current portion of lines of credit) | $16.3 million (Total lines of credit) |
Note: Revenue includes $6.7 million in license revenue from the out-licensing of the rolapitant program to TESARO, Inc. in December 2010.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 180% year-over-year, driven primarily by the full-year contribution of the OPKO Chile and Exakta-OPKO (Mexico) acquisitions and the $6.7 million license revenue from TESARO.
- Improved Gross Margin: Gross margin expanded significantly due to the high-margin license revenue (which had no associated cost of goods sold) and improved performance in the Latin American pharmaceutical operations.
- Reduced Operating Loss: The operating loss narrowed by approximately $10.8 million compared to 2009. This was largely due to a decrease in Research and Development (R&D) expenses ($7.9 million in 2010 vs. $12.9 million in 2009) following the termination of the bevasiranib Phase III trial in 2009.
- Acquisitions: In 2010, OPKO acquired Exakta-OPKO in Mexico (February 2010) and made strategic investments in Fabrus, LLC, and TESARO, Inc.
- Divestiture: The company out-licensed its rolapitant (NK-1) program to TESARO, Inc., receiving an upfront payment of $6.0 million and equity.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to incur substantial losses in the foreseeable future as it advances its product pipeline. The company plans to commercialize diagnostic tests for Alzheimer's disease (expected marketing launch in 2013) and cancer. Growth is expected to come from leveraging proprietary technology, strategic acquisitions, and expanding commercial operations in emerging markets (Chile and Mexico).
Liquidity: As of December 31, 2010, the company held $18.0 million in cash. Management believes this, combined with available credit lines and proceeds from a March 2011 public offering (net proceeds ~$96.4 million), is sufficient to fund operations for more than 12 months.
Key Risks:
- Profitability: The company has a history of operating losses and does not expect to become profitable in the near future.
- Development Risk: Technologies are in early stages; clinical trials may fail, and regulatory approval is uncertain.
- Funding: Substantial additional funding will be required, potentially through dilutive equity offerings or debt.
- Dependency: Success is heavily dependent on the molecular diagnostic program and the commercial success of partners like TESARO.
- Internal Controls: The company previously identified a material weakness in internal controls regarding the accounting for convertible preferred stock, which was remediated by December 31, 2010.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.0 million year-end cash balance plus the $96.4 million raised in March 2011 against the projected burn rate for clinical trials and operations.
- License Revenue Sustainability: Assess the likelihood of receiving future milestone payments from TESARO (up to $115 million potential) and the commercial viability of rolapitant.
- Alzheimer's Diagnostic Timeline: Monitor the progress of the validation study for the Alzheimer's blood test, with completion expected in late 2011 and marketing in 2013.
- Latin American Operations: Review the financial performance and integration of OPKO Chile and Exakta-OPKO, which are the primary sources of current product revenue.
- Debt Obligations: Confirm the status of the $12.0 million related-party line of credit with the Frost Group (renewed in Feb 2011) and the $14.7 million in Chilean credit lines.
- Preferred Stock: Note the existence of Series A and Series D Preferred Stock with liquidation preferences totaling approximately $35.5 million, which rank senior to common stock.